Total Payments
$17,163
2024 Payments
$1,185
Companies
24
Transactions
348
Medicare Patients
677
Medicare Billing
$81,982
Payment Breakdown by Category
Travel$9,824 (57.2%)
Food & Beverage$7,249 (42.2%)
Education$88.85 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $9,824 | 6 | 57.2% |
| Food and Beverage | $7,249 | 336 | 42.2% |
| Education | $88.85 | 6 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals, Ltd | $9,706 | 11 | $0 (2018) |
| ABBVIE INC. | $1,303 | 62 | $0 (2024) |
| Allergan, Inc. | $1,059 | 99 | $0 (2020) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $755.24 | 5 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $687.80 | 24 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $635.54 | 29 | $0 (2022) |
| Lundbeck LLC | $621.86 | 37 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $584.12 | 22 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $314.66 | 9 | $0 (2024) |
| Axsome Therapeutics, Inc. | $311.22 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,185 | 47 | ABBVIE INC. ($502.51) |
| 2023 | $1,021 | 42 | AbbVie Inc. ($309.01) |
| 2022 | $705.27 | 24 | Otsuka America Pharmaceutical, Inc. ($139.02) |
| 2021 | $1,148 | 56 | AbbVie Inc. ($426.62) |
| 2020 | $985.89 | 48 | Allergan, Inc. ($423.69) |
| 2019 | $757.98 | 52 | Allergan Inc. ($236.85) |
| 2018 | $11,014 | 56 | Actelion Pharmaceuticals, Ltd ($9,706) |
| 2017 | $345.48 | 23 | Allergan Inc. ($173.56) |
All Payment Transactions
348 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $28.04 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.79 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: PSYCHIATRY | ||||||
| 11/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: CNS | ||||||
| 11/15/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $7.07 | General |
| Category: PSYCHIATRY | ||||||
| 10/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $25.62 | General |
| Category: PSYCHIATRY | ||||||
| 10/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: NEUROSCIENCE | ||||||
| 10/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 09/18/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: CNS | ||||||
| 09/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Central Nervous System | ||||||
| 08/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: NEUROSCIENCE | ||||||
| 08/05/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: PSYCHIATRY | ||||||
| 08/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $32.92 | General |
| Category: Psychology/Psychiatric | ||||||
| 07/18/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.20 | General |
| Category: PSYCHIATRY | ||||||
| 07/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: NEUROSCIENCE | ||||||
| 07/01/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $9.10 | General |
| Category: PSYCHIATRY | ||||||
| 07/01/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $1.57 | General |
| Category: PSYCHIATRY | ||||||
| 06/28/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: NEUROSCIENCE | ||||||
| 06/20/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.45 | General |
| Category: PSYCHIATRY | ||||||
| 06/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 142 | 472 | $48,151 | $20,705 |
| 2022 | 4 | 165 | 474 | $54,291 | $24,698 |
| 2021 | 4 | 200 | 445 | $52,535 | $22,048 |
| 2020 | 4 | 170 | 368 | $47,156 | $14,531 |
Total Patients
677
Total Services
1,759
Medicare Billing
$81,982
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 246 | $36,900 | $13,080 | 35.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 56 | $6,720 | $4,421 | 65.8% |
| Q3014 | Telehealth originating site facility fee | Office | 2023 | 65 | 170 | $4,531 | $3,204 | 70.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 76 | 290 | $43,500 | $18,050 | 41.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 45 | $5,400 | $3,716 | 68.8% |
| Q3014 | Telehealth originating site facility fee | Office | 2022 | 64 | 116 | $3,091 | $2,231 | 72.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 13 | 23 | $2,300 | $700.64 | 30.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 84 | 237 | $35,550 | $15,827 | 44.5% |
| Q3014 | Telehealth originating site facility fee | Office | 2021 | 52 | 112 | $2,985 | $2,174 | 72.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 15 | 15 | $5,900 | $2,160 | 36.6% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 49 | 81 | $8,100 | $1,888 | 23.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 63 | 189 | $28,350 | $9,396 | 33.1% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 53 | 115 | $11,500 | $2,400 | 20.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 15 | 15 | $6,000 | $1,888 | 31.5% |
| Q3014 | Telehealth originating site facility fee | Office | 2020 | 39 | 49 | $1,306 | $845.92 | 64.8% |
About Dr. Carlos Sandoval, MD
Dr. Carlos Sandoval, MD is a Psychiatry healthcare provider based in Key Largo, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780625822.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carlos Sandoval, MD has received a total of $17,163 in payments from pharmaceutical and medical device companies, with $1,185 received in 2024. These payments were reported across 348 transactions from 24 companies. The most common payment nature is "Travel and Lodging" ($9,824).
As a Medicare-enrolled provider, Sandoval has provided services to 677 Medicare beneficiaries, totaling 1,759 services with total Medicare billing of $81,982. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Key Largo, FL
- Active Since 06/09/2006
- Last Updated 09/27/2018
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1780625822
Products in Payments
- VRAYLAR (Drug) $2,329
- REXULTI (Drug) $841.64
- ARZERRA (Drug) $755.24
- LATUDA (Drug) $584.12
- TRINTELLIX (Drug) $522.42
- BRINTELLIX (Drug) $285.16
- SPRAVATO (Drug) $273.01
- AUSTEDO (Drug) $239.37
- ARISTADA (Drug) $212.77
- Auvelity (Drug) $194.57
- ABILIFY MAINTENA (Drug) $182.86
- Trintellix (Drug) $146.49
- OCREVUS (Biological) $129.80
- Sunosi (Drug) $116.65
- Non-Covered Product (Drug) $116.30
- TYSABRI (Biological) $91.98
- ZERBAXA (Drug) $87.04
- INGREZZA (Drug) $74.88
- CAPLYTA (Drug) $51.66
- INVEGA SUSTENNA (Drug) $41.65
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.